FDA Approves Pomalidomide for Patients with AIDS-Related Kaposi Sarcoma
May 15, 2020

Pomalidomide was approved for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.

Profiling of Osteosarcoma Demonstrates Why Immunotherapy is Ineffective
February 25, 2020

Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape.

Treatment Combination May Be Effective for Antitumor Activity in Advanced Sarcoma
January 28, 2020

The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial.